IL108750A - Pharmaceutical cognition enhancing compositions containing 1,3-dialiphatic-8-(phenylalkyl or ludanyl) xanthines as selective adenosine receptor agents - Google Patents
Pharmaceutical cognition enhancing compositions containing 1,3-dialiphatic-8-(phenylalkyl or ludanyl) xanthines as selective adenosine receptor agentsInfo
- Publication number
- IL108750A IL108750A IL10875094A IL10875094A IL108750A IL 108750 A IL108750 A IL 108750A IL 10875094 A IL10875094 A IL 10875094A IL 10875094 A IL10875094 A IL 10875094A IL 108750 A IL108750 A IL 108750A
- Authority
- IL
- Israel
- Prior art keywords
- ludanyl
- dialiphatic
- xanthines
- phenylalkyl
- pharmaceutical
- Prior art date
Links
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title abstract 2
- 102000009346 Adenosine receptors Human genes 0.000 title 1
- 108050000203 Adenosine receptors Proteins 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 230000019771 cognition Effects 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 title 1
- 230000007278 cognition impairment Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2350193A | 1993-02-26 | 1993-02-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL108750A0 IL108750A0 (en) | 1994-05-30 |
| IL108750A true IL108750A (en) | 2000-09-28 |
Family
ID=21815459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL10875094A IL108750A (en) | 1993-02-26 | 1994-02-23 | Pharmaceutical cognition enhancing compositions containing 1,3-dialiphatic-8-(phenylalkyl or ludanyl) xanthines as selective adenosine receptor agents |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5840729A (xx) |
| EP (1) | EP0686155B1 (xx) |
| JP (1) | JPH08512281A (xx) |
| KR (1) | KR100315898B1 (xx) |
| CN (1) | CN1041418C (xx) |
| AT (1) | ATE169019T1 (xx) |
| AU (1) | AU680241B2 (xx) |
| CA (1) | CA2155130C (xx) |
| DE (1) | DE69412073T2 (xx) |
| DK (1) | DK0686155T3 (xx) |
| ES (1) | ES2120025T3 (xx) |
| HU (1) | HUT72677A (xx) |
| IL (1) | IL108750A (xx) |
| MX (1) | MX9401406A (xx) |
| NO (1) | NO311920B1 (xx) |
| NZ (1) | NZ262984A (xx) |
| TW (1) | TW261532B (xx) |
| WO (1) | WO1994019349A1 (xx) |
| ZA (1) | ZA941176B (xx) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303624B1 (en) * | 1997-03-18 | 2001-10-16 | Fujisawa Pharmaceutical Co., Ltd. | Preventives and remedies for hyperphosphatemia |
| NZ508314A (en) | 1998-06-02 | 2004-03-26 | Osi Pharm Inc | Pyrrolo[2,3d]pyrimidine compositions and their use |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US20020115635A1 (en) * | 2001-02-21 | 2002-08-22 | Pnina Fishman | Modulation of GSK-3beta activity and its different uses |
| DK1450811T3 (da) | 2001-11-30 | 2010-02-15 | Osi Pharm Inc | Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf |
| KR20040068317A (ko) | 2001-12-20 | 2004-07-30 | 오에스아이 파마슈티컬스, 인코포레이티드 | 피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도 |
| US6982335B2 (en) * | 2002-05-15 | 2006-01-03 | Genzyme Corporation | Synthesis of substituted thiazoline carboxylic acids |
| WO2004086047A2 (en) * | 2003-03-28 | 2004-10-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1) |
| AU2004296137A1 (en) * | 2003-12-09 | 2005-06-23 | Kyowa Hakko Kirin Co., Ltd. | Preventive and/or therapeutic agent for higher brain dysfunction |
| US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| WO2007095161A2 (en) * | 2006-02-14 | 2007-08-23 | New York University | Methods and compositions for treating disorders associated with increased bone turnover and osteopenia |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3843117A1 (de) * | 1988-12-22 | 1990-06-28 | Boehringer Ingelheim Kg | Neue xanthinderivate mit adenosin-antagonistischer wirkung |
| US5047534A (en) * | 1990-03-26 | 1991-09-10 | Merrell Dow Pharmaceuticals Inc. | Selective adenosine receptor agents |
| DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| JPH0455150A (ja) * | 1990-06-22 | 1992-02-21 | Takata Kk | 助手席用エアバッグ装置 |
| US5087827A (en) * | 1991-02-11 | 1992-02-11 | Tektronix, Inc. | Variable voltage transition circuit |
| US5208240A (en) * | 1991-03-12 | 1993-05-04 | Merrell Dow Pharmaceuticals Inc. | 8-substituted purines as selective adenosine receptor agents |
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
-
1994
- 1994-01-27 CA CA002155130A patent/CA2155130C/en not_active Expired - Fee Related
- 1994-01-27 AU AU62968/94A patent/AU680241B2/en not_active Ceased
- 1994-01-27 EP EP94910661A patent/EP0686155B1/en not_active Expired - Lifetime
- 1994-01-27 AT AT94910661T patent/ATE169019T1/de not_active IP Right Cessation
- 1994-01-27 WO PCT/US1994/001009 patent/WO1994019349A1/en active IP Right Grant
- 1994-01-27 CN CN94191309A patent/CN1041418C/zh not_active Expired - Fee Related
- 1994-01-27 DK DK94910661T patent/DK0686155T3/da active
- 1994-01-27 NZ NZ262984A patent/NZ262984A/en unknown
- 1994-01-27 DE DE69412073T patent/DE69412073T2/de not_active Expired - Fee Related
- 1994-01-27 JP JP6518986A patent/JPH08512281A/ja active Pending
- 1994-01-27 US US08/500,991 patent/US5840729A/en not_active Expired - Fee Related
- 1994-01-27 ES ES94910661T patent/ES2120025T3/es not_active Expired - Lifetime
- 1994-01-27 KR KR1019950703577A patent/KR100315898B1/ko not_active IP Right Cessation
- 1994-01-27 HU HU9502495A patent/HUT72677A/hu unknown
- 1994-02-21 ZA ZA941176A patent/ZA941176B/xx unknown
- 1994-02-22 TW TW083101485A patent/TW261532B/zh active
- 1994-02-23 IL IL10875094A patent/IL108750A/xx not_active IP Right Cessation
- 1994-02-24 MX MX9401406A patent/MX9401406A/es not_active IP Right Cessation
-
1995
- 1995-08-25 NO NO19953353A patent/NO311920B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2155130C (en) | 1994-09-01 |
| HUT72677A (en) | 1996-05-28 |
| TW261532B (xx) | 1995-11-01 |
| HU9502495D0 (en) | 1995-10-30 |
| DE69412073T2 (de) | 1999-02-18 |
| DE69412073D1 (de) | 1998-09-03 |
| AU6296894A (en) | 1994-09-14 |
| ES2120025T3 (es) | 1998-10-16 |
| CN1118599A (zh) | 1996-03-13 |
| ZA941176B (en) | 1994-09-20 |
| NO953353D0 (no) | 1995-08-25 |
| MX9401406A (es) | 1994-08-31 |
| NO953353L (no) | 1995-08-25 |
| NZ262984A (en) | 1997-05-26 |
| NO311920B1 (no) | 2002-02-18 |
| ATE169019T1 (de) | 1998-08-15 |
| AU680241B2 (en) | 1997-07-24 |
| WO1994019349A1 (en) | 1994-09-01 |
| EP0686155B1 (en) | 1998-07-29 |
| CN1041418C (zh) | 1998-12-30 |
| KR100315898B1 (ko) | 2002-02-28 |
| DK0686155T3 (da) | 1999-02-01 |
| CA2155130A1 (en) | 1994-09-01 |
| IL108750A0 (en) | 1994-05-30 |
| EP0686155A1 (en) | 1995-12-13 |
| JPH08512281A (ja) | 1996-12-24 |
| US5840729A (en) | 1998-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL117848A0 (en) | Novel compounds a process for their production and pharmacetical compositions containing same | |
| IL108520A0 (en) | Imidazopyridine derivatives, processes for the preparation thereof, and pharmaceutical compositions containing them | |
| EP0664792A4 (en) | ANTAGONISTS OF FIBRINOGENIC RECEPTORS. | |
| IL132153A0 (en) | Novel compounds | |
| NO952229L (no) | Anvendelse av karbamazepin og okskarbazepin ved behandling av neurologiske lesjoner relatert til traumatiske skader | |
| GR3020975T3 (en) | Application of carbamazepine and oxcarbazepine in the treatment of parkinson's disease and parkinsonian syndromes. | |
| IL110672A0 (en) | Therapeutic heterocycles | |
| IL108750A (en) | Pharmaceutical cognition enhancing compositions containing 1,3-dialiphatic-8-(phenylalkyl or ludanyl) xanthines as selective adenosine receptor agents | |
| EE9900315A (et) | Pürrolo[3,4-d]pürimidinooni derivaadid ja nende kasutamine ravimitena | |
| IL124091A (en) | Use of 1-(2-naphth-2-ylethyl)-4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine for the preparation of pharmaceutical compositions for the treatment of amyotrophic lateral sclerosis and pharmaceutical compositions containing it | |
| IL112999A0 (en) | Crystalline salts of 2,3,4,5- tetrahydro -1h-3-benzazepine compounds, their preparation and pharmaceutical compositions containing them | |
| FI932490A0 (fi) | Underenhetsvaccin mot Neisseria meningitidis-infektioner och motsvarande underenheter i rent tillstaond | |
| GB9507883D0 (en) | Compounds | |
| IL104817A0 (en) | Sugar derivatives of macrolides | |
| IL107917A0 (en) | Triazoloquinazolines, their preparation and their use as medicaments | |
| IL108283A0 (en) | Use of riluzole for promoting restoration following radiation | |
| MX9802000A (es) | Sales de adicion de acido de compuestos de 2,3,4,5-tetrahidro-1h-3-benzacepina. | |
| NZ304823A (en) | Beta carboline derivatives and medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| RH1 | Patent not in force |